[go: up one dir, main page]

NO20082133L - Immunoglobulin-fusjonsproteinformuleringer - Google Patents

Immunoglobulin-fusjonsproteinformuleringer

Info

Publication number
NO20082133L
NO20082133L NO20082133A NO20082133A NO20082133L NO 20082133 L NO20082133 L NO 20082133L NO 20082133 A NO20082133 A NO 20082133A NO 20082133 A NO20082133 A NO 20082133A NO 20082133 L NO20082133 L NO 20082133L
Authority
NO
Norway
Prior art keywords
fusion protein
compositions
immunoglobulin fusion
protein formulations
lyophilized
Prior art date
Application number
NO20082133A
Other languages
English (en)
Inventor
Li Li
Nicholas W Warne
Anthony Barry
Thomas Crowley
Daniel Dixon
Jennifer Juneau
Ajaj Kumar
Nicholas Luksha
Michael Shamashkin
Erin Soley
Chandra A Webb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20082133L publication Critical patent/NO20082133L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SAMMENDRAG Det beskrives blandinger av Ig-fusjonsproteiner, spesielt blandinger som inneholder et Ig-fusjonsprotein, et fyllmiddel, et disakkarid, et overflateaktivt middel og en buffer. I henhold til ett aspekt er disse blandingene stabile under langtidslagring eller i det minste én fryse/tine-syklus. Videre beskrives fremgangsmåter for fremstilling av Ig-fusjonsproteinblandingene. I henhold til ett aspekt er blandingene lyofilisert. I henhold til et annet aspekt er blandingene lyofilisert etter en fremgangsmåte som innbefatter et kjøletrinn.
NO20082133A 2005-11-22 2008-05-07 Immunoglobulin-fusjonsproteinformuleringer NO20082133L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73927105P 2005-11-22 2005-11-22
PCT/US2006/045059 WO2007062040A1 (en) 2005-11-22 2006-11-21 Immunoglobulin fusion protein formulations

Publications (1)

Publication Number Publication Date
NO20082133L true NO20082133L (no) 2008-06-16

Family

ID=37781927

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082133A NO20082133L (no) 2005-11-22 2008-05-07 Immunoglobulin-fusjonsproteinformuleringer

Country Status (14)

Country Link
US (2) US20070237758A1 (no)
EP (1) EP1951305A1 (no)
JP (1) JP2009516692A (no)
KR (1) KR20080071192A (no)
CN (1) CN101312744A (no)
AU (1) AU2006318583A1 (no)
BR (1) BRPI0618893A2 (no)
CA (1) CA2630115A1 (no)
CR (1) CR10012A (no)
EC (1) ECSP088459A (no)
NO (1) NO20082133L (no)
RU (1) RU2008118166A (no)
SV (1) SV2009002911A (no)
WO (1) WO2007062040A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006272804B2 (en) * 2005-07-22 2011-02-24 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CN101600457B (zh) * 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
EP2124890A2 (en) * 2007-02-16 2009-12-02 Wyeth a Corporation of the State of Delaware Use of sucrose to suppress mannitol-induced protein aggregation
CN105168123B (zh) * 2007-11-12 2019-03-08 阿雷斯贸易股份有限公司 Taci-免疫球蛋白融合蛋白制剂
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2010148337A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
CN101693016B (zh) * 2009-11-02 2012-07-25 北京美福源生物医药科技有限公司 通用的注射用重组人血清白蛋白融合蛋白制剂配方
NZ599783A (en) 2009-11-03 2013-10-25 Grifols Therapeutics Inc Composition and use for alpha-1 proteinase inhibitor
KR101567901B1 (ko) * 2009-11-24 2015-11-10 그리폴스 테라퓨틱스 인코포레이티드 동결건조 방법, 조성물, 및 키트
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
HRP20180959T1 (hr) 2011-01-28 2018-07-27 Sanofi Biotechnology Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN104940926B (zh) 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
GB201513010D0 (en) 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
IL314925A (en) 2015-08-18 2024-10-01 Regeneron Pharma Antibodies against PCSK9 for the treatment of patients with hyperlipidemia undergoing lipoprotein-lowering therapy
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CN110607555B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种制备紫杉醇单晶或无定型物的方法
CN111195349B (zh) * 2018-11-16 2023-02-24 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干粉制剂
MX2021008017A (es) * 2019-01-06 2021-08-05 Endo Global Aesthetics Ltd Formulaciones de colagenasa y metodos de produccion de las mismas.
EP3917618A1 (en) 2019-01-31 2021-12-08 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
EP3959240A1 (en) 2019-04-24 2022-03-02 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
AU2020288561A1 (en) 2019-06-04 2021-12-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating pain in subjects with rheumatoid arthritis
CN113125489A (zh) * 2019-12-31 2021-07-16 上海药明生物技术有限公司 生物制剂配方优化和工艺优化的方法和系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP3900664B2 (ja) * 1997-09-26 2007-04-04 株式会社ニコン 顕微鏡
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
ES2435141T3 (es) * 1999-02-22 2013-12-18 University Of Connecticut Nuevas formulaciones de factor VIII libres de albúmina
CA2371427A1 (en) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
US20030180287A1 (en) * 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
EP1720519A1 (en) * 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization

Also Published As

Publication number Publication date
EP1951305A1 (en) 2008-08-06
SV2009002911A (es) 2009-03-04
ECSP088459A (es) 2008-06-30
AU2006318583A1 (en) 2007-05-31
CA2630115A1 (en) 2007-05-31
KR20080071192A (ko) 2008-08-01
JP2009516692A (ja) 2009-04-23
RU2008118166A (ru) 2009-12-27
US20070237758A1 (en) 2007-10-11
WO2007062040A1 (en) 2007-05-31
US20110033464A1 (en) 2011-02-10
CR10012A (es) 2008-07-29
BRPI0618893A2 (pt) 2011-09-13
CN101312744A (zh) 2008-11-26

Similar Documents

Publication Publication Date Title
NO20082133L (no) Immunoglobulin-fusjonsproteinformuleringer
NO20065084L (no) Interferon-alfa polypeptider og konjugater
DK1888761T3 (da) Rekombinante N-glycosylerede proteiner fra prokaryote celler
NO20074278L (no) Tigecyklinblandinger og fremgangsmater for fremstilling
MX2021005723A (es) Enzima y sistema crispr-cas12j.
WO2004042017A3 (en) Methods and compositions for increasing antibody production
DK1422237T3 (da) Fremgangsmåder til rekombinant frembringelse af antifusogene peptider
RU2009149604A (ru) Способ предоставления устойчивого к температуре миорелаксанта на основе нейротоксичного компонента ботулинического токсина в твердой форме
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
AR054667A1 (es) Composicion hemostatica que comprende acido hialuronico
WO2008121324A3 (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
DK1513937T3 (da) Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
WO2012018639A3 (en) Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
ES2379283T3 (es) Proteínas de unión a albúmina sérica
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
NO20052363L (no) Interferon-alfa polypeptider og konjugater
WO2006020935A3 (en) Stabilizing formulations
CY1110157T1 (el) Χιμαιρικα ανασυνδυασμενα αντιγονα του toxoplasma gondii
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
EA201100071A1 (ru) Новые композиции и способы
DK1610819T3 (da) Stabiliserende formulering til immunoglobulin-G-sammensætninger i flydende eller frysetørret form
WO2004024750A3 (en) Cd44-binding ligands
AR063899A1 (es) Materiales plasticos
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application